Skip to main content
main-content

The independent medical news service

Kidney cancer

15-11-2018 | Oncology | News | Article

Genomic annotation improves MSKCC risk model for renal carcinoma

Adding the mutation status of three genes linked to renal cell carcinoma improves the prognostic value of the Memorial Sloan Kettering Cancer Center risk model for patients receiving tyrosine kinase inhibitors for metastatic disease, research shows.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30648-X
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30674-0

26-10-2018 | Oncology | News | Article

ESMO 2018

First-line avelumab–axitinib outperforms sunitinib in advanced RCC

Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.

Source:

ESMO 2018; Munich, Germany; 19–23 October

13-07-2018 | Kidney cancer | News | Article

Germline mutations detected in advanced RCC patients

Germline mutations may be common in patients with advanced renal cell carcinoma and may have the potential to guide therapy if detected, US researchers report.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.1986

19-06-2018 | Oncology | Main feed | News

ASCO 2018 in brief

IMmotion151 PROs add support for first-line atezolizumab plus bevacizumab in mRCC

Patient-reported outcomes from the IMmotion151 study favor atezolizumab plus bevacizumab as a first-line regimen for the treatment of patients with metastatic clear cell renal cell carcinoma.

19-06-2018 | Kidney cancer | News | Article

ASCO 2018

Need for nephrectomy challenged in some sunitinib-treated metastatic renal cancers

Results of the phase III CARMENA trial show that treatment with sunitinib alone is as good as treatment with nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic renal cell carcinoma.

Source:

ASCO Annual Meeting 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

22-05-2018 | Non-small-cell lung cancer | Main feed | News

approvalsWatch

Atezolizumab receives NICE recommendation for NSCLC

Read more on this UK decision here

26-04-2018 | Kidney cancer | News | Article

approvalsWatch

FDA backs nivolumab plus ipilimumab for first-line advanced RCC

Click for the details of this announcement

23-03-2018 | Kidney cancer | News | Article

Promising early data reported for avelumab plus axitinib in advanced RCC

Results from the JAVELIN Renal 100 study suggest that avelumab plus axitinib is a tolerable combination, with encouraging antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

Source:

Lancet Oncol 2018; Advance online publication

20-02-2018 | Kidney cancer | News | Article

Phase Ib trial shows promising treatment combination for advanced RCC

Axitinib plus pembrolizumab can be tolerated and shows promising antitumor activity in patients with advanced renal cell carcinoma, researchers from an early-stage US trial say.

Source:

Lancet Oncol 2018; Advance online publication

15-02-2018 | Kidney cancer | News | Article

IMmotion151 supports atezolizumab–bevacizumab for untreated metastatic RCC

In patients with previously untreated metastatic renal cell carcinoma, progression-free survival is significantly longer with the combination of atezolizumab and bevacizumab than with sunitinib, phase III study findings indicate.

Source:

ASCO GU 2018; San Francisco, California, USA

19-01-2018 | Kidney cancer | News | Article

News in brief

METEOR supports cabozantinib for patients with advanced RCC and bone metastases

Treatment with the multikinase inhibitor cabozantinib is associated with better outcomes than everolimus therapy in patients with previously treated advanced renal cell carcinoma and bone involvement, suggests a prespecified subgroup analysis of the phase III METEOR trial.

15-01-2018 | Oncology | News | Article

Risks of combining immunotherapy with targeted therapy, radiation highlighted

Adding immune checkpoint inhibitors to targeted therapy or radiotherapy can worsen some of the toxic effects associated with these treatment modalities, indicate two reports published in JAMA Oncology.

Source:

JAMA Oncol 2018; Advance online publication

21-12-2017 | Oncology | News | Article

approvalsWatch

FDA approvals announced for advanced RCC, CML

Read more on these decisions here

23-11-2017 | Oncology | News | Article

approvalsWatch

FDA announces approvals for sunitinib, obinutuzumab

More details on these decisions are a click away

21-09-2017 | Oncology | News | Article

approvalsWatch

Bevacizumab biosimilar approved in USA

More details about this decision are just a click away

15-09-2017 | Kidney cancer | News | Article

ESMO 2017

Nivolumab–ipilimumab duo ‘a new standard of care’ in first-line advanced RCC

Phase III trial results presented at the ESMO 2017 Congress support the use of nivolumab plus ipilimumab for the first-line treatment of patients with advanced or metastatic clear-cell renal cell carcinoma.

14-07-2017 | Oncology | Main feed | News

approvalsWatch

Tivozanib, ribociclib EMA authorizations extend oncology armamentarium

Click here for details on these decisions

13-07-2017 | Kidney cancer | News | Article

Savolitinib has potential in MET-driven papillary RCC

Savolitinib, a highly selective MET tyrosine kinase inhibitor, shows activity in patients with MET-driven advanced papillary renal cell carcinoma, researchers report.

Source:

J Clin Oncol 2017; Advance online publication

28-06-2017 | Kidney cancer | Conference report | Article

ASCO 2017

Combining checkpoint blockade with targeted therapy in first-line advanced RCC

This report provides an overview of three studies investigating the combination of immunotherapy with targeted agents in treatment-naïve patients with locally advanced or metastatic renal cell carcinoma.

Source:

J Clin Oncol 2017; 35: 4504, 4505, 4506

16-03-2017 | Kidney cancer | News | Article

High-risk clear cell RCC survival not ASSUREd with sunitinib, sorafenib

Adjuvant treatment with sunitinib or sorafenib does not prolong disease-free survival or overall survival in clear cell renal cell carcinoma patients classed as high risk, shows a post hoc analysis of the placebo-controlled ASSURE trial.

Source:

JAMA Oncol 2017; Advance online publication

image credits